NexImmune Statistics
Total Valuation
NexImmune has a market cap or net worth of 286,465. The enterprise value is -2.14 million.
| Market Cap | 286,465 |
| Enterprise Value | -2.14M |
Important Dates
The next estimated earnings date is Friday, March 7, 2025.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NexImmune has 1.39 million shares outstanding. The number of shares has increased by 15.46% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.39M |
| Shares Change (YoY) | +15.46% |
| Shares Change (QoQ) | +10.39% |
| Owned by Insiders (%) | 15.51% |
| Owned by Institutions (%) | 0.77% |
| Float | 1.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.10 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.12 |
Financial Position
The company has a current ratio of 0.66
| Current Ratio | 0.66 |
| Quick Ratio | 0.51 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -232.97% and return on invested capital (ROIC) is -115.60%.
| Return on Equity (ROE) | -232.97% |
| Return on Assets (ROA) | -72.69% |
| Return on Capital (ROIC) | -115.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -3.44M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.37% in the last 52 weeks. The beta is 1.81, so NexImmune's price volatility has been higher than the market average.
| Beta (5Y) | 1.81 |
| 52-Week Price Change | -91.37% |
| 50-Day Moving Average | 0.26 |
| 200-Day Moving Average | 1.85 |
| Relative Strength Index (RSI) | 44.39 |
| Average Volume (20 Days) | 6,000 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.06M |
| Pretax Income | -20.62M |
| Net Income | -20.62M |
| EBITDA | -16.38M |
| EBIT | -17.06M |
| Earnings Per Share (EPS) | -17.39 |
Balance Sheet
| Cash & Cash Equivalents | 2.42M |
| Total Debt | n/a |
| Net Cash | 2.42M |
| Net Cash Per Share | 1.74 |
| Equity (Book Value) | 696,350 |
| Book Value Per Share | 0.50 |
| Working Capital | -1.61M |
Cash Flow
In the last 12 months, operating cash flow was -17.61 million and capital expenditures -981, giving a free cash flow of -17.61 million.
| Operating Cash Flow | -17.61M |
| Capital Expenditures | -981 |
| Free Cash Flow | -17.61M |
| FCF Per Share | -12.62 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NexImmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.46% |
| Shareholder Yield | -15.46% |
| Earnings Yield | -8,465.94% |
| FCF Yield | -6,146.02% |
Stock Splits
The last stock split was on October 19, 2023. It was a reverse split with a ratio of 0.04.
| Last Split Date | Oct 19, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |